Huntington National Bank Acquires 1,201 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Huntington National Bank lifted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 161.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,946 shares of the medical equipment provider’s stock after purchasing an additional 1,201 shares during the period. Huntington National Bank’s holdings in Lantheus were worth $214,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Signaturefd LLC boosted its stake in shares of Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 92 shares in the last quarter. GAMMA Investing LLC boosted its position in Lantheus by 184.1% during the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 208 shares during the period. UMB Bank n.a. grew its holdings in Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after purchasing an additional 126 shares during the last quarter. Kathleen S. Wright Associates Inc. bought a new position in shares of Lantheus in the third quarter valued at approximately $51,000. Finally, Nkcfo LLC acquired a new stake in shares of Lantheus in the second quarter worth $47,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Price Performance

Shares of LNTH stock opened at $76.83 on Monday. The stock has a market cap of $5.34 billion, a P/E ratio of 12.78 and a beta of 0.51. The stock has a fifty day moving average price of $104.95 and a 200 day moving average price of $96.65. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $126.89.

Analyst Upgrades and Downgrades

LNTH has been the topic of several recent analyst reports. StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a report on Friday, November 8th. B. Riley boosted their price objective on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Redburn Atlantic assumed coverage on Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price on the stock. Truist Financial reiterated a “buy” rating and set a $120.00 price target (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, JMP Securities lowered their price objective on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 7th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $122.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.